EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Similar Posts
EyeCRO Contributes to Evaluation of SPVN06 Gene Therapy
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.
eyecro and NeuMedics announce collaboration to utilize MiDROPS™ technology for the development of NM108
Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation…
One CRO. Complete Dataset.
When a preclinical efficacy study wraps up at EyeCRO, ocular tissues move directly from our animal facility to our bioanalytical lab. No third-party handoffs. No waiting in an external lab’s queue. Sponsors receive a single integrated dataset covering both in-life endpoints and bioanalytical quantitation from the team that ran the entire study. LC-MS/MS Quantitation Our…
EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease
Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…
EyeCRO Contributes to LUXTURNA® Potency Assay Validation
We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…
